![](https://endpts.com/wp-content/uploads/2022/04/downward-trend-shutterstock-scaled.jpg)
Credit: Shutterstock
The good, the bad and lots of just plain old ugly: The Q1 numbers are in
Anyone expecting much upbeat news for biotech in Q1 of this year was in for a sore disappointment.
Our numbers czar, DealForma’s Chris Dokomajilar, crunched …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.